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Abstract Gastric carcinogenesis occurs when gastric
epithelial cells transition through the initial, immortal,
premalignant, and malignant stages of transformation.
Epigenetic regulations contribute to this multistep process.
Due to the critical role of epigenetic modifications, these
changes are highly likely to be of clinical use in the future
as new biomarkers and therapeutic targets for the early
detection and treatment of cancers. Here, we summarize
the recent findings on how epigenetic modifications,
including DNA methylation, histone modifications, and
non-coding RNAs, regulate gastric carcinogenesis, and we
discuss potential new strategies for the diagnosis and
treatments of gastric cancer. The strategies may be helpful
in the further understanding of epigenetic regulation in
human diseases.
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Introduction
The latest figures from the World Health Organization
(WHO) show that 951,600 new gastric cancer cases and
723,100 gastric cancer-related deaths occurred globally in
2012 [1]. The overall incidence of gastric cancer has
declined. However, in China, the morbidity and mortality
of gastric cancer rank 2nd and 3rd, respectively, among all
malignant tumors [2]. Gastric cancer is classified into the
following two subtypes: diffuse and intestinal. Usually,
intestinal gastric cancers retain a glandular structure and
undergo multiple processes as follows: chronic inflamma-
tion, atrophy, intestinal metaplasia, and atypical
hyperplasia and eventually into gastric cancer. However,
diffuse gastric cancer is relatively rare and is poorly dif-
ferentiated to the extent that no glandular structure is
recognizable. At present, no clear precancerous lesions of
diffuse gastric cancer have been defined [3, 4]. Heli-
cobacter pylori (H. pylori) infection plays an important
carcinogenic role in both subtypes of gastric cancer. Many
trials have demonstrated the possibility of cancer preven-
tion through H. pylori screening and eradication. The
malignant transformation of gastric mucosa involves mul-
timolecular events, including gene mutation [5] and
epigenetic alteration [6]. This study presents a review of
the roles of epigenetic alterations in the malignant trans-
formation of gastric mucosa.
The concept and significance of epigenetics
The concept of epigenetics was first proposed by
Waddington [7]. Epigenetics refers to the heritable changes
in gene expression that are independent of variations in
DNA sequences. The main types of epigenetic processes
include DNA methylation, histone modification, and
chromatin remodeling as well as the function of non-cod-
ing RNA (ncRNA). The basic theory of classical genetics
cannot adequately explain the biodiversity within species.
For example, identical twins carrying the same DNA
sequences may exhibit distinct phenotypes and different
susceptibility to diseases. The proposal of epigenetics has
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compensated for such shortcoming of classical genetic
theory. Epigenetics is a component of normal physiological
regulation, and abnormal epigenetic regulation may lead to
tumorigenesis. Studies have suggested that intestinal-type
gastric cancer originates from chronic gastritis, which
gradually progresses through stages of chronic atrophic
gastritis, intestinal metaplasia, and atypical hyperplasia and
ultimately develops into advanced gastric cancer [8, 9].
During the malignant transformation of gastric mucosa, a
large number of genes are subjected to epigenetic regula-
tion. The genes show cumulative changes as the disease
evolves [10, 11].
Methylation of tumor suppressor genes is
an important mechanism responsible
for malignant transformation of gastric mucosa
Methylation is a type of chemical modification that occurs
in DNA sequences. In mammalian cells, DNA methylation
occurs almost exclusively at the fifth carbon atom of the
cytosine residues within cytosine–phosphate–guanine
(CpG) dinucleotides. CpG dinucleotides tend to form CG-
rich clusters called CpG islands. CpG islands are mainly
distributed in the core promoter sequence and transcription
start site of structural genes. DNA methylation may induce
changes in chromatin structure, DNA conformation, DNA
stability, and the interactions between DNA and protein,
resulting in transcription inhibition [12]. Two adverse
phenomena characterize the process of carcinogenesis:
locus-specific hypermethylation and global depletion of
methyl groups from cancer genomes. Hypermethylation of
promoters has been widely shown to contribute to the
silencing of tumor suppressor genes during carcinogenesis.
Global hypomethylation of the cancer genome was initially
shown to cause genome-wide allelic instability, but
recently, the involvement of this process in transcriptional
gene regulation has become increasingly recognized
[13, 14].
Promoter hypermethylation-induced inactivation of
tumor suppressor genes is an important mechanism that
leads to gastric carcinogenesis [15]. For example, CDH1,
the gene encoding epithelial cadherin (E-cadherin), is a
tumor suppressor gene located on chromosome 16q22.1.
E-cadherin is expressed in normal epithelium and plays a
role in calcium-dependent cell adhesion. CDH1 is hyper-
methylated in 40–80 % of human primary gastric
carcinoma. In diffuse gastric cancer, a methylation-induced
decrease in E-cadherin expression has been observed in
more than 50 % of the undifferentiated early cancers and
adjacent non-cancerous gastric epithelial tissues. There-
fore, CDH1 methylation-induced loss of E-cadherin
expression is an early event in the malignant
transformation of gastric mucosa [16, 17]. E-cadherin is
also inactivated by mutation and accounts for the heredi-
tary nature of diffuse-type gastric cancer [18]. Runt-related
transcription factor 3 (RUNX3) is a key molecule in the
transforming growth factor-b (TGF-b) signaling pathway.
The expression of RUNX3 is significantly reduced in
gastric cancer. The main reason for the decreased RUNX3
expression is DNA hypermethylation in the promoter
region. Kim et al. found that RUNX3 CpG island methy-
lation occured in 8.1 % of chronic gastritis cases, 28.1 %
of intestinal metaplasia cases, 27.3 % of gastric adeno-
carcinoma cases, 64 % of primary gastric cancer cases, and
60 % of gastric cancer cell lines [19]. In RUNX3 knockout
mice, apoptosis is inhibited. These mice show hypertrophy
of gastric mucosa and intestinal metaplasia of gastric
epithelial cells, indicating that RUNX3 hypermethylation
plays an important role in the malignant transformation of
intestinal-type gastric cancer [20, 21]. In addition, chronic
gastritis, intestinal metaplasia, gastric adenoma, and gastric
cancer show an increasing frequency of p16/cyclin-de-
pendent kinase inhibitor 2A (CDKN2A) methylation
[22–24]. This finding indicates that p16/CDKN2A methy-
lation occurs at the initial stage of gastric mucosal
malignant transformation and undergoes cumulative
change as the disease progresses. Genes related to the
malignant transformation of gastric mucosa that undergoes
promoter methylation also include the retinoblastoma (RB)
gene, von Hippel–Lindau (VHL) tumor suppressor gene,
breast cancer 1 (BRCA1) gene, human mutL homolog 1
(hMLH1) gene, X-ray repair cross-complementation group
1 (XRCC1) gene, and ADAM metallopeptidase with
thrombospondin type 1 motif 9 (ADAMTS9) gene [25, 26].
In gastric cancer, the distribution characteristics of gene
methylation are correlated with biological tumor charac-
teristics and patient prognosis. Patrick Tan and colleagues
investigated DNA methylation profiles of 240 primary
gastric cancers and gastric cancer cell lines [27]. It has
been found that methylomes are widely distributed in
gastric cancers. However, these results need to be further
verified. In addition, previous data on the methylation of
gastric mucosal transformation-related genes are mainly
derived from experimental studies of previously estab-
lished cell lines or small-sized clinical tissue specimen
studies. The current knowledge on gene methylation is far
from being accurate and comprehensive. Future studies
focusing on the following aspects will be more valuable:
(1) longitudinal studies: large-scale DNA methylation
profiling of clinical tissue specimens—longitudinal,
dynamic cohort studies that analyze serial clinical speci-
mens obtained from individual patients at various stages,
from inflammation, intestinal metaplasia, and atypical
hyperplasia to gastric cancer, are particularly inadequate; a
genome-wide longitudinal study of DNA methylation
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based on such specimens will provide more accurate and
comprehensive results; (2) data mining: collection and
analysis of the data on gene methylation in normal gastric
mucosa, precancerous lesions, and gastric cancer in various
populations—exploration of the methylation pattern chan-
ges that occur during the malignant transformation of
gastric mucosa using large-scale data mining allows a
complete understanding of the gene methylation charac-
teristics related to the malignant transformation of gastric
mucosa as well as the differentiation of the key methylation
changes from the numerous accompanying changes; and
(3) non-CpG methylation: non-CpG methylation is an
emerging field of research [28, 29]. However, a few data
have been obtained for gastric cancer. The research on the
distribution, recognition, and regulation of non-CpG
methylation in gastric cancer will further deepen our
understanding of epigenetic regulation in the transforma-
tion of gastric mucosa.
The histone code affects the malignant
transformation of gastric mucosa
In eukaryotes, DNA, histones, and non-histone proteins are
arranged in a highly ordered pattern to form chromatin.
Histones are divided into five classes, including nucleoso-
mal core histones (H2A, H2B, H3, and H4) and linker
histones (H1). Each core histone consists of a globular
structural domain and an N-terminal tail that is exposed on
the surface of the nucleosome. A variety of covalent
modifications may occur at the N-terminus of the core
histones, including acetylation, methylation, phosphoryla-
tion, ubiquitination, and glycosylation. These histone
modifications alter the chromatin structure and, therefore,
determine the state of gene activation/inactivation; these
modifications also regulate physiological processes in the
cells. Different histone modifications are orchestrated in
both time and space, forming a complex regulatory net-
work known as the ‘‘histone code.’’ Numerous studies have
demonstrated histone modification changes in gastric can-
cer, and such changes are of great clinical significance
[30, 31]. Recent studies of gastric cancer-related histone
modifications have mainly focused on histone acetylation,
methylation, and phosphorylation.
Histone acetylation: histone acetylation is coregulated
by histone acetyltransferases (HATs) and histone
deacetylases (HDACs). Histone acetylation promotes
transcription, whereas histone deacetylation inhibits tran-
scription. Abnormal expression of HDACs and HATs is
frequently observed in gastric precancerous lesions and
gastric cancer [32, 33]. Current studies have found that
histone deacetylation occurs at the promoter region of a
number of genes in gastric cancer, including p21(WAF1/
CIP1) [34], RIP-associated ICH1/CED3-homologous pro-
tein with a death domain (RAIDD) [35], DTW domain
containing 1 (DTWD1) [36], p53 upregulated modulator of
apoptosis (PUMA) [31], gelsolin and retinoic acid receptor
beta [37], deleted in liver cancer-1 (DLC1) [38], and
thioredoxin-interacting protein (TXNIP) [39]. In addition,
histone deacetylation has been shown to be positively
correlated with the downregulated expression of the above
genes.
Histone methylation: histone methylation mainly occurs
at the lysine (K) and arginine (R) residues of H3 and H4
and is regulated by histone methyltransferases (HMTs) and
histone demethylases (HDMs). There are three types of
histone methylation: monomethylation, dimethylation, and
trimethylation. Different sites and types of histone
methylation confer different functions. Methylation of
H3K9 and H4K20 inhibits gene expression, whereas
methylation of H3K4, H3K36, and H3K79 activates gene
expression. H3K27 monomethylation activates gene
expression, whereas H3K27 dimethylation and trimethy-
lation inhibit gene expression. For example, H3K27
trimethylation inhibits the expression of Arg kinase-bind-
ing protein 2 (ArgBP2) in gastric cancer [40].
Histone phosphorylation: phosphorylation can disrupt
the interaction between histones and DNA, and renders the
chromatin structure unstable. In addition, phosphorylation
may create a surface that binds to protein recognition
modules, thereby allowing interaction with specific protein
complexes. These two mechanisms enable histone phos-
phorylation to play a role in chromosome condensation/
separation, transcription activation, apoptosis, and DNA
damage repair. Studies on the role of histone phosphory-
lation in the malignant transformation of gastric mucosa
are insufficient. Fehri et al. found that H. pylori infection
reduces the phosphorylation levels of histone H3S10 and
H3T3 in gastric epithelial cells, thus regulating the cell
cycle [41]. This finding may represent an important
mechanism of H. pylori-induced gastric carcinogenesis. In
addition, an increased phosphorylation level of histone H3
was shown to be closely related to the histological type,
vascular infiltration, and lymph node metastasis of gastric
cancer and is an independent factor associated with a poor
prognosis in patients with gastric cancer [42]. The findings
indirectly support the hypothesis that histone phosphory-
lation is involved in the malignant transformation of gastric
mucosal cells.
However, relevant studies remain focused on the rela-
tionships between the changes in the overall level of certain
histone modifications and various pathological states dur-
ing gastric mucosal carcinogenesis. Studies investigating
the mechanisms through which histone modifications affect
the malignant transformation of gastric mucosa are cur-
rently lacking. To pinpoint the genes or signaling pathways
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through which histone modifications affect the malignant
transformation of gastric mucosa, studies that utilize his-
tone modification-specific antibodies to coprecipitate
chromatin or those that employ oligonucleotide microar-
rays or deep DNA sequencing to identify significantly
differentially modified gene loci/chromatin segments and
then combine these discoveries with gene function verifi-
cation would be beneficial.
Non-coding RNAs regulate the malignant
transformation of gastric mucosal epithelial cells
Non-coding RNA (ncRNA) is a general term for an RNA
molecule that does not encode a protein. ncRNAs include
micro RNA (miRNA), piwi-interacting RNA (piRNA),
long non-coding RNA (lncRNA), transfer RNA (tRNA),
and ribosomal RNA (rRNA). A large number of studies
have focused on the roles of miRNAs and lncRNAs in
gastric carcinogenesis.
MiRNAs
MiRNAs are a class of evolutionarily conserved, endoge-
nous, non-protein-coding small RNAs. MiRNAs
participate in the malignant transformation of gastric
mucosal cells by negatively regulating the expression of
target genes.
Abnormal expression of miRNA molecules
in gastric cancer
Petrocca et al. compared the miRNA expression profiles
between tissues with histological signs of chronic gastritis
and normal gastric mucosa [43]. It has been found that, in
chronic gastritis, the expression of miR-1 and miR-155 is
upregulated, whereas the expression of miR-20, miR-26b,
miR-202, miR-203, and miR-205 is downregulated. Ueda
et al. examined miRNA expression in 160 paired samples
of gastric cancer tissues and non-cancerous tissues [44].
The authors found that the expression of 22 miRNAs is
upregulated, while the expression of 13 miRNAs is
downregulated in gastric cancer tissues compared with the
non-cancerous tissues. In addition, 83 % of the patients
with gastric cancer could be accurately diagnosed based on
miRNA expression profiles in tissue specimens. Microarray
analysis has been performed to examine miRNA expres-
sion in gastric cancer tissue specimens collected in a large
number of countries and geographical regions. The results
have shown that the expression of miR-21 [45], miR-27a
[46] and miR-196a [47] is significantly elevated in gastric
cancer, whereas the expression of lethal-7 (let-7) miRNA
[48], miR-101 [49, 50], and miR-29a [51] is markedly
reduced. These results clearly demonstrate that miRNAs
are involved in gastric carcinogenesis. However, the con-
sistency of previous results is poor. This may be due to
sample variation. At present, there is no generally accepted
characteristic miRNA expression profile of gastric cancer.
Further studies of large and multicenter sample
cohort(s) are needed.
Abnormal expression of miRNAs significantly affects
the malignant phenotype of gastric cancer cells
The expression of miR-847 is decreased in gastric cancer,
which activates the signal transducer and activator of tran-
scription 3 (STAT3)/vascular endothelial growth factor A
(VEGF-A) pathway, increases tumor angiogenesis, and
promotes the development and progression of gastric cancer
[52]. The expression of miR-145 is upregulated in gastric
cancer, which inhibits the expression of catenin (cadherin-
associated protein), delta 1 (CTNND1), and N-cadherin
while promoting the translocation of CTNND1 and E-cad-
herin from the cytoplasm to the cell membrane. As a result,
the proliferation and metastasis of gastric cancer cells are
promoted, and the apoptosis of gastric cancer cells is
inhibited [53]. The expression of the miR-106b-25 cluster is
upregulated in gastric cancer, which inhibits the TGF-b
pathway, induces the downregulation of the expression of
cyclin-dependent kinase inhibitor 1A (CDKN1A) and
BCL2-like 11 apoptosis facilitator (BCL2L11), and pro-
motes the development and progression of gastric cancer
[43]. Our study demonstrated that the expression of miR-17-
5p is significantly increased in gastric cancer tissues. High
miR-17-5p expression inhibits suppressor of cytokine sig-
naling 6 (SOCS6), which promotes the proliferation of
gastric cancer cells [54]. The expression of miR-296-5p is
abnormally increased in gastric cancer, which inhibits the
expression of caudal-related homeobox 1 (CDX1). Further-
more, miR-296-5p/CDX1 affects the phosphorylation level
of the extracellular signal-regulated kinases 1 and 2 (ERK1/
2) through the mitogen-activated protein kinase (MAPK)/
ERK pathway and induces changes in the expression levels
of the cell cycle-related protein cyclin D1 and the apoptosis-
related proteins B-cell lymphoma 2 (Bcl2) and BCL2-as-
sociated X (Bax), thus maintaining the survival of gastric
cancer cells and regulating cell proliferation [55]. In addi-
tion, miR-150 [56], miR-149 [57], miR-7 [58], miR-199a-5p
[59], miR-206 [60, 61], miR-19a/b [62], and miR-218
[63, 64] are all involved in the development and progression
of gastric cancer (Fig. 1).
LncRNA
LncRNA refers to a class of RNA molecules greater than
200 nucleotides (nt) in length that are transcribed mainly
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by RNA polymerase II, that lack apparent open reading
frames (ORFs) and that do not encode proteins. However,
lncRNAs participate in the regulation of a variety of
intracellular signaling processes (including tumorigenesis)
through the modification of chromatins, activation of
transcription, and interference with transcription. Recent
studies have shown that several lncRNAs are abnormally
expressed in gastric cancer. Moreover, abnormal expres-
sion of lncRNAs plays an important role in the
development, progression, invasion, and metastasis of
gastric cancer.
HOX transcript antisense intergenic RNA (HOTAIR) is
located on chromosome 12q13.13. HOTAIR is a 2158-nt
lncRNA that possesses a trans-regulatory function. The 50
end of HOTAIR binds to the initiation complex known as
polycomb repressive complex 2 (PRC2). Binding of
HOTAIR to PRC2 induces the phosphorylation of EZH2, a
subunit of PRC2, at threonine 345 and the subsequent
trimethylation of chromosome-bound histone H3K27,
thereby inhibiting the expression of the target genes. In
addition, the 30 end of HOTAIR binds to the lysine-specific
demethylase 1 (LSD1)/REST corepressor 1 (CoREST)/re-
pressor element 1 (RE1) silencing transcription factor
(REST) complex, which mediates histone H3K4me2
demethylation and, thereby, regulates the transcriptional
activity of target genes. HOTAIR expression is signifi-
cantly increased in gastric cancer tissues compared with
paracancerous tissues. In diffuse gastric cancer, the high
HOTAIR expression group exhibits drastically increased
invasion and lymph node metastasis and a decreased
overall survival rate in comparison with the low HOTAIR
expression group. In addition, studies have shown that
inhibition of HOTAIR expression in gastric cancer cells
decreases the expression of matrix metalloproteinases 1
and 3, reduces the invasive capability of cancer cells, and
reverses the epithelial–mesenchymal transition (EMT) in
gastric cancer cells. These findings demonstrate that
HOTAIR plays an important role in the development and
progression of gastric cancer [65–67]. The H19 gene (full
length: 2.5 kb) is located on the human chromosome
11p15.5 region and contains a total of 5 exons and 4
introns. The processed, mature H19 has a length of 2.3 kb.
Due to the lack of obvious ORFs, H19 is defined as an
lncRNA. H19 expression is significantly elevated in gastric
cancer tissues compared with paracancerous tissues [68].
Overexpression of H19 enhances the proliferative capacity
Fig. 1 NcRNA-oriented
network in the malignant
transformation process of
gastric cancer. This
figure provides insight into the
roles of ncRNA and its related
protein in the malignant
transformation of gastric
mucosal cells. It can be seen
that a complex network
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of the cells, whereas small interfering RNA (siRNA)-me-
diated interference of H19 expression enhances apoptosis.
The effects of overexpression and downregulation of H19
are related to the inactivation and activation of the TP53
gene. Recent studies have shown that transcription of the
H19 gene also produces a mature miRNA, namely, miR-
675. H19 is capable of regulating the progression of gastric
cancer through the H19/miR-675/runt-related transcription
factor 1 (RUNX1) signaling axis [69, 70]. In addition,
tumor suppressor candidate 7 (TUSC7) [71], maternally
expressed 3 (MEG3) [72], BM742401 [73], colon cancer-
associated transcript 1 (CCAT1) [74], and multidrug
resistant (MDR)-related and upregulated lncRNA (MRUL)
[75] have been found to be differentially expressed
between gastric cancer cells and normal gastric mucosal
cells and affect the malignant phenotype of gastric cancer
cells.
Current studies in the field of ncRNAs have mainly
focused on the effects of such molecules on the malignant
phenotypes of gastric cancer cells, including growth, pro-
liferation, metastasis, and drug resistance. The conclusion
that ncRNAs participate in the malignant transformation of
gastric mucosal cells is based on the findings that ncRNAs
are differentially expressed between normal gastric muco-
sal cells and gastric cancer cells and that the differential
expression of ncRNAs induces functional changes in cer-
tain malignant phenotype of gastric cancer cells. There are
virtually no functional studies that directly address the
malignant transformation of normal gastric mucosa. In
addition, the intrinsic link between various ncRNA mole-
cules remains unclear. We simulated the interactions
between a number of gastric carcinogenesis-related mole-
cules that have been identified by our study or reported in
the literature. However, further biological experiments are
required to discover the ncRNA-regulated network.
H. pylori infection promotes gastric cancer mainly
through epigenetic regulation
H. pylori infection is the most important risk factor
for gastric cancer. The epigenetic changes induced by H.
pylori compose one of the principal molecular mechanisms
of gastric carcinogenesis.
H. pylori infection and gene methylation
Numerous studies have demonstrated that H. pylori infec-
tion is closely related to abnormal CpG island methylation.
Maekita et al. found that methylation levels of all the
detected regions were much higher in H. pylori-positive
samples than in H. pylori-negative samples among healthy
volunteers [76]. Nakajima et al. analyzed the promoter
methylation of CpG islands of 48 genes that may be
methylated in gastric cancer cell lines. The results showed
that 26 genes were consistently methylated in individuals
with current or past infection by H. pylori [77]. Shin et al.
identified quite distinct methylation profiles according to
the presence or absence of current H. pylori infection in
non-cancerous gastric mucosae from patients with gastric
cancer [78]. Cheng concluded that FOXD3-mediated
transcriptional control of tumor suppressors is deregulated
by H. pylori infection-induced hypermethylation. This in
turn could affect the suppression of gastric tumors [79].
These findings indicate that H. pylori infection potently
induces CpG island methylation and may be responsible
for the initiation of gastric carcinogenesis.
H. pylori-mediated chronic inflammation is one of the
important causes of DNA methylation. A number of studies
have suggested that methylation levels in the gastric
mucosa after H. pylori infection decrease after H. pylori
eradication [80, 81]. These data support the idea that H.
pylori-mediated inflammation induces methylation. How-
ever, how the inflammation triggers DNA methylation is
not yet known.
H. pylori infection and histone modification
A relatively few studies have investigated whether H.
pylori affects histone modifications. The infection of gas-
tric epithelial cells with H. pylori leads to hyperacetylation
of histone H4 [82], which induces the binding of histone
H1 to ATP [83] and causes histone H3 dephosphorylation
and deacetylation [41, 84]. These changes result in the
abnormal expression of oncogenes and tumor suppressor
genes [85, 86], which contributes to malignant transfor-
mation of gastric epithelial cells.
H. pylori infection is a major cause of abnormal
miRNA expression
MiRNAs play an important role in H. pylori infection-in-
duced malignant transformation of gastric mucosa. Zhang
et al. demonstrated for the first time that H. pylori infection
is able to induce changes in miRNA expression profiles
[87]. They found that miR-21 expression is significantly
increased in H. pylori-positive gastric tissues, indicating
that the increased expression of miR-21 may be related to
H. pylori infection. In AGS human gastric carcinoma cells,
H. pylori infection promotes the secretion of nuclear factor
kappa B (NF-jB) and interleukin 6 (IL-6) and activates
activator protein 1 (AP-1) and STAT3, resulting in sig-
nificantly upregulated miR-21 expression and drastically
enhanced cell proliferative and invasive capabilities. Using
miRNA microarrays, Matsushima et al. identified 55
miRNAs that were differentially expressed between H.
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pylori-positive and H. pylori-negative endoscopic biopsy
specimens [88]. Among the 55 miRNAs, the expression of
30 miRNAs was significantly reduced. A portion of the
miRNAs (including miR-223, miR-375, and miR-200c)
was found to be significantly correlated with gastric
mucosal inflammatory activity, chronic inflammation, and
H. pylori infection severity scores. Correlation analysis
showed that 8 miRNAs can be used to accurately predict
whether H. pylori infection is present. Infection of the cells
with an H. pylori strain containing the wild-type CagA
(cytotoxin-associated gene A) structural domain induced
changes in the expression of certain miRNAs (e.g., let-7,
miR-125a, and miR-500), whereas H. pylori strains with
mutant CagA showed no such effect. Studies conducted by
Saito et al. showed that miR-17 and miR-20a are also
involved in the gastric cancer-promoting signaling path-
ways mediated by CagA [89, 90]. CagA activates c-Myc
through the activation of the Erk pathway, which further
stimulates the expression of miR-17 and miR-20a. MiR-
20a is capable of suppressing p21 expression. In addition,
miR-146a [91], miR-155 [92], and miR-218 [93] are also
involved in H. pylori infection-related malignant transfor-
mation of gastric mucosa. In a study conducted by
Matsushima et al., patients who tested positive for H. pylori
infection were successfully cured with an anti-H. pylori
regimen and were reexamined 4 weeks after eradication of
H. pylori infection [88]. Cure of the H. pylori infection not
only restored the levels of 14 miRNAs whose expression
was downregulated during H. pylori infection but also
significantly reduced the levels of a portion of the miRNAs
whose expression was upregulated by H. pylori infection.
This phenomenon indicates that downregulation/inhibition
of the expression of cancer-promoting miRNAs using
methods, such as oligonucleotides and miRNA sponges
combined with the introduction of exogenous cancer-sup-
pressing miRNAs, may reduce or even partially block the
promoting effect of H. pylori on gastric cancer.
The effects of various types of epigenetic regulations
(such as DNA methylation, histone modification, and
ncRNA) on the malignant transformation of gastric mucosa
are not independent. Instead, the epigenetic effects interact
synergistically to promote gastric carcinogenesis. In addi-
tion, different epigenetic changes may coordinate in the
regulation of the expression of one carcinogenesis-related
gene (Fig. 2). For example, ubiquitin-like containing PHD
and RING finger domains 1 (UHRF1) is known to maintain
DNA methylation via the recruitment of DNA methyl-
transferase 1 (DNMT1) [94]. We identified and verified
miR-146a/b as direct upstream regulators of UHRF1 [95].
Duursma et al. found that miR-148 targets human
DNMT3b [96]. MiR-146a/b and miR-148 can regulate
RUNX3 expression via the effects of UHRF1 and DNMT1
on promoter methylation. In addition, increased H3K9
dimethylation and reduced H3 acetylation synergistically
inhibit the transcription of RUNX3 [97, 98]. Moreover,
miR-130b [99], miR-301a [100], miR-106a [101], miR-
103a [102], miR-495 [103], and miR-532-5p [104] directly
inhibit RUNX3 translation at the post-transcriptional level.
Decreased RUNX3 expression directly downregulates
miR-30a expression, which enhances the expression of the
miR-30a target gene vimentin and promotes EMT in gas-
tric cancer cells [105]. RUNX3 regulates gastric cancer cell
proliferation via the TGF-b [106] and Wnt [107, 108]
pathways and affects angiogenesis in gastric cancer by
regulating the expression of vascular endothelial growth
factor (VEGF) [109]. In contrast, different epigenetic
changes may regulate the expression of different carcino-
genesis-related genes, whereby they cooperate to promote
the malignant transformation of gastric mucosa.
Conclusions
The exploitation of characteristic epigenetic alterations
during the malignant transformation of gastric mucosa
allows for the prevention, diagnosis, treatment, and prog-
nostic evaluation of gastric cancer from a new perspective
independent of protein expression. For example, it has been
reported that promoter methylation of death-associated
protein kinase (DAPK) [110], E-cadherin [111], and p16
[112] genes may serve as a criterion for sensitive and
specific diagnosis of gastric cancer. We have found that the
methylation status of the ring finger protein 180 (RNF180)
gene may be used to predict the malignant potential of
intestinal metaplasia and atypical hyperplasia of gastric
mucosa and diagnose early gastric cancer (unpublished
data). Currently, we have established a fluorescence-based
quantitative technique that enables the analysis of RNF180
gene methylation and meets the registration requirements
for diagnostic reagents. We have initiated a clinical trial
application to test this diagnostic kit.
The reversibility of epigenetic alterations (such as DNA
methylation and histone modification) has recently become
a hot topic in drug development. Studies have found that
inhibition of deacetylase may suppress the malignant
phenotype of gastric cancer cells [39, 113–116] and
increase the sensitivity of gastric cancer cells to
chemotherapy [115, 117, 118]. Histone deacetylase inhi-
bitors, such as Vorinostat (Zolinza, suberoylanilide
hydroxamic acid, SAHA) developed by Merck & Co., Inc.
(USA) and Chidamide developed in China, have been
successfully used in the clinical treatment of cancer
[119–121]. Currently, a number of DNA methyltransferase
inhibitors (DNMTi) and histone deacetylase inhibitors are
undergoing clinical trials to assess their safety and efficacy
for the treatment of tumors [122, 123].
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However, unfavorable epigenetic changes induced by
epigenetic drugs may lead to severe side effects. The dis-
covery of ways by which the specificity against tumor cells
can be enhanced and the side effects can be reduced is still
a hot topic. The epigenetic modifications and their com-
binations that are involved in the malignant transformation
of gastric mucosa are highly complex and diverse. There
are many outstanding issues requiring clarification. In-
depth studies and further elucidation of the epigenetic
networks that regulate the malignant transformation of
gastric mucosa will provide a wealth of pathways and
targets for understanding gastric cancer development and
progression, conducting molecular typing, establishing new
therapies, and developing new drugs.
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